Novartis Challenger To Alexion Advances In Rare Kidney Disease

Ultomiris Head-to-Head Planned

 
• By Andrew McConaghie
  
Novartis NIBR Cambridge, MA
Analysts at Jefferies think iptacopan could hit $3.6bn in peak annual sales. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip